Guruv Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 5 Year, 29 Days
- Last Filing with ROC 31 Mar 2022
- Revenue 183.30%
(FY 2022)
- Profit 582.38%
(FY 2022)
- Ebitda 132.81%
(FY 2022)
- Net Worth 4.40%
(FY 2022)
- Total Assets 2.12%
(FY 2022)
About Guruv Pharmaceutical
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Krishnamurthy, Sekar Chettiar, Baalachandar Sekar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24290TN2019PTC132934
- Company No.
132934
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2019
- Date of AGM
30 Dec 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Guruv Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnamurthy  | Additional Director | 15-Oct-2021 | Current |
| Sekar Chettiar | Director | 23-Sep-2023 | Current |
| Baalachandar Sekar | Director | 23-Sep-2023 | Current |
| Pradeep | Director | 08-Jan-2020 | Current |
Financial Performance of Guruv Pharmaceutical.
Guruv Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 183.3% increase. The company also saw a substantial improvement in profitability, with a 582.38% increase in profit. The company's net worth moved up by a moderate rise of 4.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Guruv Pharmaceutical?
In 2022, Guruv Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Chennai Oscar Bio Pharmaceuticals Private LimitedActive 11 years 8 months
Sekar Chettiar and Baalachandar Sekar are mutual person
- Om Dhan Naturals Private LimitedActive 3 years 3 months
Sekar Chettiar and Baalachandar Sekar are mutual person
- Krebz Healthcare Private LimitedActive 20 years 10 months
Sekar Chettiar and Baalachandar Sekar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Guruv Pharmaceutical?
Unlock and access historical data on people associated with Guruv Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Guruv Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Guruv Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
